Biofrontera Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biofrontera's earnings have been declining at an average annual rate of -7.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 13.8% per year.

Anahtar bilgiler

-7.5%

Kazanç büyüme oranı

51.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı13.8%
Özkaynak getirisi-123.8%
Net Marj-38.3%
Sonraki Kazanç Güncellemesi13 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Sep 28
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Aug 09
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

May 24
Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Dec 30
Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Nov 13
The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Oct 18
Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours

Oct 05

Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

Sep 06

Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance

Aug 12

Biofrontera announces 2Q prelim product revenues

Jul 12

Gelir ve Gider Dağılımı

Biofrontera nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:BFRI Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2435-14351
31 Mar 2433-23380
31 Dec 2334-20380
30 Sep 2334-26380
30 Jun 2329-23380
31 Mar 2328-14360
31 Dec 2229-1350
30 Sep 2228-12240
30 Jun 2228-26330
31 Mar 2229-29290
31 Dec 2124-38260
30 Sep 2124-23320
30 Jun 2122-10190
31 Mar 2119-10170
31 Dec 2019-11180
31 Dec 1926-11280

Kaliteli Kazançlar: BFRI is currently unprofitable.

Büyüyen Kar Marjı: BFRI is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BFRI is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.

Büyüme Hızlandırma: Unable to compare BFRI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: BFRI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Özkaynak Getirisi

Yüksek ROE: BFRI has a negative Return on Equity (-123.82%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin